Stock ARROWHEAD RESEARCH CORP
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Arrowhead Research Corp Nasdaq

Equities

US0427972098

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Arrowhead Pharmaceuticals Lung Disease Treatment Study Shows Lower Serum sRAGE in Asthma Patients
MT
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
BU
Arrowhead Pharmaceuticals : TIDES USA 2024 TIDES 2024 AdiposeTIDES 2024 ARO-SOD1
PU
Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 08:40 AM
UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating
MT
Arrowhead Pharmaceuticals : 2024 Second Quarter Results Prepared Remarks
PU
Arrowhead Pharmaceuticals Swings to Loss in Fiscal Q2
MT
Transcript : Arrowhead Pharmaceuticals, Inc., Q2 2024 Earnings Call, May 09, 2024
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
BU
Arrowhead Nets $50 Milestone Payment from Royalty Pharma After Completion of Enrollment in Trial of Cardiovascular Drug
MT
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
BU
Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
BU
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
BU
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
BU
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
BU
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
CI
Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
CI
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
BU
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BU
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARWR Stock
  4. Stock
  5. News Arrowhead Research Corp